Charting Pharma Manufacturing Trends: Part Two

Charting Pharma Manufacturing Trends: Part Two

Building on insights from CRB’s Horizons: Life Sciences 2025 report, this second installment of our conversation with Peter Walters, Fellow of Advanced Therapies at CRB, explores the modalities driving forward momentum across the life sciences industry, the expanding role of standardization in manufacturing networks, and how tariffs and domestic investment strategies are shaping the future of pharma manufacturing.

If you missed Part One, catch our discussion on the rise of continuous manufacturing and its growing adoption across large pharma.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(129)

Accelerating Biopharma Manufacturing Through Integrated Automation

Accelerating Biopharma Manufacturing Through Integrated Automation

Biopharmaceutical manufacturers are facing mounting pressure to scale production faster while maintaining quality and operational reliability due to the ever-expanding pipeline of therapies. Meanwhile...

30 Kesä 21min

The Future of Global Biopharma Manufacturing Networks

The Future of Global Biopharma Manufacturing Networks

Amid ongoing geopolitical uncertainty, regional manufacturing initiatives, and evolving supply chain risks reshaping the pharmaceutical industry, manufacturers are rethinking how biologics are produce...

23 Kesä 12min

Building Flexibility into Biopharma Manufacturing

Building Flexibility into Biopharma Manufacturing

As biopharma pipelines become more complex and market conditions continue to evolve, manufacturers are rethinking how they scale capacity, deploy capital, and build supply chains. The industry’s focus...

16 Kesä 19min

How Biocatalysis Is Changing Pharma Manufacturing

How Biocatalysis Is Changing Pharma Manufacturing

Interest in macrocyclic peptides (MCPs) continues to grow, which means manufacturers are facing mounting pressure to develop production methods capable of supporting commercial-scale demand of these m...

9 Kesä 19min

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part Two

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part Two

As peptide therapeutics become larger, more complex, and increasingly purity-sensitive, manufacturers are confronting a new layer of execution challenges. Long-chain peptides introduce compounding sca...

2 Kesä 20min

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part One

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part One

Peptide pipelines continue to expand globally, and pharmaceutical companies are increasingly turning to CDMOs earlier in the development lifecycle to help manage growing technical and operational comp...

26 Touko 20min

Solutions Spotlight: Managing Chloramines in Pharmaceutical Water Systems

Solutions Spotlight: Managing Chloramines in Pharmaceutical Water Systems

As municipal water utilities increasingly shift from free chlorine to chloramine disinfection strategies, pharmaceutical manufacturers are facing new challenges in maintaining consistent, high-purity ...

22 Touko 17min

Can CDMO-to-CDMO Collaboration Simplify Drug Development?

Can CDMO-to-CDMO Collaboration Simplify Drug Development?

Amid increasing complexity in the drug development landscape, CDMOs are exploring new ways to streamline the path from early-stage formulation through commercial manufacturing. Rather than operating i...

19 Touko 19min

Suosittua kategoriassa Politiikka ja uutiset

uutiscast
aikalisa
ootsa-kuullut-tasta-2
rss-ootsa-kuullut-tasta
rss-podme-livebox
tervo-halme
otetaan-yhdet
politiikan-puskaradio
rss-asiastudio
the-ulkopolitist
rss-raha-talous-ja-politiikka
aihe
rss-vaalirankkurit-podcast
rss-girls-finish-f1rst
rss-mina-ukkola
rss-kaikki-uusiksi
rss-360-podi
rss-fingo-podcast
rss-kuka-mina-olen
rss-ulkopoditiikkaa